Eric Colman

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Anorectics on trial: a half century of federal regulation of prescription appetite suppressants
    Eric Colman
    UDivision of Metabolic and Endocrine Drug Products, U S Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, Maryland 20857, USA
    Ann Intern Med 143:380-5. 2005
  2. ncbi Dinitrophenol and obesity: an early twentieth-century regulatory dilemma
    Eric Colman
    Division of Metabolism and Endocrinology Products, Office of Drug Evaluation II, Center for Drug Evaluation and Research, U S Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
    Regul Toxicol Pharmacol 48:115-7. 2007
  3. ncbi An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system
    Eric Colman
    Division of Metabolism and Endocrinology Products, United States Food and Drug Administration, Silver Spring, MD 20993, USA
    Pharmacoepidemiol Drug Saf 17:1068-76. 2008
  4. ncbi A brief history of calcitonin
    Eric Colman
    Division of Metabolic and Endocrine Drug Products, US Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD 20857, USA
    Lancet 359:885-6. 2002

Collaborators

Detail Information

Publications4

  1. ncbi Anorectics on trial: a half century of federal regulation of prescription appetite suppressants
    Eric Colman
    UDivision of Metabolic and Endocrine Drug Products, U S Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, Maryland 20857, USA
    Ann Intern Med 143:380-5. 2005
    ..Sibutramine, the latest anorectic to enter the market, is now the focus of a landmark trial that is examining, for the first time, whether drug-induced weight loss reduces the risk for fatal and nonfatal cardiovascular disease...
  2. ncbi Dinitrophenol and obesity: an early twentieth-century regulatory dilemma
    Eric Colman
    Division of Metabolism and Endocrinology Products, Office of Drug Evaluation II, Center for Drug Evaluation and Research, U S Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
    Regul Toxicol Pharmacol 48:115-7. 2007
    ....
  3. ncbi An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system
    Eric Colman
    Division of Metabolism and Endocrinology Products, United States Food and Drug Administration, Silver Spring, MD 20993, USA
    Pharmacoepidemiol Drug Saf 17:1068-76. 2008
    ..We detected disproportionate reporting of amyotrophic lateral sclerosis (ALS) with HMG-CoA-reductase inhibitors (statins) in the Food and Drug Administration's (FDA) spontaneous adverse event (AE) reporting system (AERS)...
  4. ncbi A brief history of calcitonin
    Eric Colman
    Division of Metabolic and Endocrine Drug Products, US Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD 20857, USA
    Lancet 359:885-6. 2002